Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to the manufacture of pharmaceutical products for the prevention and treatment of allergic respiratory diseases such as allergic rhinoconjunctivitis and allergic rhinitis - asthma and specialized. The therapy solutions with tablets and drops are used in the immunotherapy of allergy patients to use.

Company Key

2011, the annual turnover of 235 million Euro International Stallergenes and thus is now the seventh largest pharmaceutical company in France. The company employs over 1,000 employees.

Company History

Stallergenes was founded in 1962 in Lyon at the Institute Institut Mérieux. Until 1974, the company based in the advanced Benelux and North Africa. In the late 1980s Stallergenes could deliver some of the world's first orally administered anti-allergy vaccines. In 1989, led Stallergenes and the Institute Pasteur its manufacturing activities together and started a joint research project, 1998, the company was listed on the stock exchange.

In 2002, the first sublingual immunotherapy solutions have been introduced in various countries in 2008, the 5Gräsertablette was introduced in Germany, was die2009 finally registered for 23 European countries. In 2011, a eneue production unit of raw materials was opened. Stallergenes is the world leader in the production of allergen extracts consisting of grass and birch pollen and house dust mites.

In 2012 more than 1000 employees working in 17 subsidiaries of the company. As a research pharmaceutical companies Stallergenes invests 20% of its turnover in research and development of innovative therapies so as to make its contribution in the treatment and cure allergies and prevent the occurrence of complications.